Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 29 Sep 2009):

Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction.

Full Abstract

BACKGROUND: To assess the safety of symptom-limited exercise testing in patients with New York Heart Association class II-IV heart failure symptoms due to left ventricular systolic dysfunction, we investigated the frequency of all-cause fatal and nonfatal major cardiovascular (CV) events among subjects enrolled in a prospective clinical trial (HF-ACTION). We hypothesized that exercise testing would be safe, as defined by a rate for all-cause death of <0.1 per 1,000 tests and a rate of nonfatal CV events <1.0 per 1,000 tests. METHODS: Before enrollment and at 3, 12, and 24 months after randomization, subjects were scheduled to complete a symptom-limited graded exercise test with open-circuit spirometry for analysis of expired gases. To ensure the accurate reporting of exercise test-related events, we report deaths and nonfatal major CV events per 1,000 tests at months 3, 12, or 24 after randomization. RESULTS: A total of 2,331 subjects were randomized into HF-ACTION. After randomization, 2,037 subjects completed 4,411 exercise tests. There were no test-related deaths, exacerbation of heart failure or angina requiring hospitalization, myocardial infarctions, strokes, or transient ischemic attacks. There was one episode each of ventricular fibrillation and sustained ventricular tachycardia. There were no exercise test-related implantable cardioverter defibrillator discharges requiring hospitalization. These findings correspond to zero deaths per 1,000 exercise tests and 0.45 nonfatal major CV events per 1,000 exercise tests (95% CI 0.11-1.81). CONCLUSIONS: In New York Heart Association class II-IV patients with severe left ventricular systolic dysfunction, we observed that symptom-limited exercise testing is safe based on no deaths and a rate of nonfatal major CV events that is <0.5 per 1,000 tests.

 

Author information

Author/s: Keteyian, Steven J (SJ); Isaac, Debra (D); Thadani, Udho (U); Roy, Brad A (BA); Bensimhon, Daniel R (DR); McKelvie, Robert (R); Russell, Stuart D (SD); Hellkamp, Anne S (AS); Kraus, William E (WE); HF-ACTION Investigators;

Affiliation: Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA. sketeyi1(-atsign-)hfhs.org

Journal and publication information

Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

Journal: American heart journal (Am Heart J), published in United States. (Language: eng)

Reference: 2009-Oct; vol 158 (issue 4 Suppl) : pp S72-7

Dates: Created 2009/09/28; Completed 2009/10/29;

PMID: 19782792, status: MEDLINE (last retrieval date: 10/29/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: Angiotensin II Type 1 Receptor Blockers (0)

Related articles

These are the highest related articles currently in the database:

See 100+ related articles.

Related Article Map

8/30/1999
6/29/2007
Higher Relevance Score (100)
Lower Relevance Score (79)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.

© Advanogy LLC 2003-2009 - All rights reserved. Terms of Use | Contact Us | Index